CAM 17.1: A New Diagnostic Marker for Pancreatic Cancer
Author Information
Author(s): F Gansaugel, S Gansauge, N Parker, MI Beger, B Poch, KH Link, F Safi, Hans G Beger
Primary Institution: University of Ulm
Hypothesis
The study investigates the expression and release of CAM 17.1 in pancreatic carcinoma cell lines and tissue specimens.
Conclusion
CAM 17.1 shows similar sensitivity to CA 19-9 but higher specificity for pancreatic cancer, especially in distinguishing it from chronic pancreatitis.
Supporting Evidence
- The sensitivity of CAM 17.1 was found to be 67% in pancreatic cancer patients.
- The specificity of CAM 17.1 was 90% in chronic pancreatitis patients.
- CAM 17.1 levels increased with the advancement of tumor stage.
- CAM 17.1 showed a significant positive correlation with CA 19-9 levels.
- CAM 17.1 was overexpressed in 76% of pancreatic adenocarcinoma specimens.
Takeaway
Researchers found a new marker called CAM 17.1 that helps doctors tell if someone has pancreatic cancer, and it works better than some older tests.
Methodology
The study used immunohistochemistry and FACS analysis to evaluate CAM 17.1 expression in pancreatic tissues and cell lines, and serum levels were measured using ELISA.
Participant Demographics
Patients included 91 with pancreatic cancer (79 ductal adenocarcinoma, 12 cystadenocarcinoma), 93 with chronic pancreatitis, and 30 healthy blood donors.
Statistical Information
P-Value
0.22
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website